SUSD3, a novel gene within the E2/ER signaling pathway, is particularly associated with immune modulation and has been identified as a potential biomarker for the therapeutic sensitivity of aromatase inhibitors (AIs) in breast cancer treatment (10). Here, SUSD3 is linked to breast carcinoma.